42 results about "Melanoma patient" patented technology

Methods to treat cancer patients, especially melanoma patients, who have BRAF mutations and have become resistant to BRAF mutant kinase inhibitors employ inhibitors of multiple receptor tyrosine kinases. In addition, methods are described for identifying pharmaceutical compositions and drugs that will be successful in treating these patients.

This invention relates to compositions comprising haptenized tumor cells and extracts thereof, methods for preparing the compositions, vaccines comprising such haptenized tumor cells, and methods for treating cancer with such vaccines. In a specific embodiment, melanoma cells are haptenized with a dinitrophenyl group, and used for treatment of melanoma patients having metastatic disease. Preferably, patients are given a first vaccine dose containing haptenized cells to “prime” the immune system. Subsequently, patients are injected with an immunomodulatory compound such as cyclophosphamide. In a preferred embodiment, an appropriate time period after the “priming” vaccine dose, additional vaccine doses containing a mixture of haptenized cells and an adjuvant are administered. The described treatment plan is more effective for eliciting favorable anti-tumor immune responses.

The invention relates to the technical field of biological medicines, and particularly relates to application of Bepridil or KB-R7943 in preparation of a medicine for treating melanoma. The inventionprovides a new strategy for resisting melanoma, namely the inhibitor Bepridil or KB-R7943 of a sodium-calcium exchanger is applied to treat melanoma, and belongs to new application of an old medicine.The mechanism of Bepridil or KB-R7943 for killing tumor cells is completely different from that of the conventional medicine, and drug resistance is not generated. Due to the use of the two new medicines, prognosis of a patient suffering from melanoma is expected to be improved, the survival rate of the patient is increased, the social burden is relieved, and bright prospect is brought to treatment of melanoma.

The invention belongs to the technical field of formulas of edible-medicinal foods and new resource foods, and particularly provides a non-total-nutrient formula food, specific total-nutrient formula food or total-nutrient formula food for patients suffering from the melanoma. The formula is made according to the requirements of the <General Rules for Formula Foods for Special Medical Purposes>, and is combined with the physical characteristics of patients suffering from the melanoma. The formula food provided by the invention is prepared by reasonably mixing various 'edible-medicinal' traditional Chinese medicines according to the quintessence theory of traditional Chinese medicine, and is prepared by mixing essences which are extracted from various edible-medicinal traditional Chinese medicines by adopting a prehydrolysis SBE technique, short peptides extracted from biological enzymolysis, prebiotics, amino acid, carbohydrate, grease with a function of keeping healthy, various vitamins and mineral substances and other technologies. The formula food can be used as a single nutrient source satisfying the nutrient demands of patients suffering from the melanoma, and has the efficacy of clearing away heat and toxic materials, removing toxic materials and blood stasis, strengthening body resistance and inhibiting cancers, benefiting qi and nourishing blood, and strengthening immunity.

The invention discloses a biomarker for predicting tumor drug sensitivity and a related product thereof, wherein the biomarker is HLA-F, CLHC1 and / or ELFN1, and the product comprises a reagent for detecting the expression level of the biomarker. The biomarker and the related product thereof are used for predicting the sensitivity of metastatic melanoma patients to an immunotherapy drug MAGE-A3, clinical medication is guided by using the biomarker and the related product thereof provided by the technical scheme of the invention, not only can the blindness of drug selection be avoided, but also the treatment effect of the drug can be monitored in the treatment process, and the purposes of medication reasonability and individualized treatment are achieved.

The invention discloses the application of the ASMT / CYP1A1 molecular signature in predicting the clinical prognosis or immune characteristics of solid tumors. The inventors studied the transcriptome and genome data of 6,658 tumor samples from 14 kinds of solid tumors, and conducted a large-scale bioinformatics analysis, confirming that the ratio of ASMT / CYP1A1 in different solid tumors is related to the clinical prognosis and tumor mutation level of patients. , Tumor neoantigen load relationship. Among them, the clinical prognosis of cervical cancer, gastric cancer, and melanin patients in the High Index group was more impressive. The results of multivariate analysis showed that ASMT / CYP1A1 was an independent predictor of clinical prognosis in cancer patients; in addition, in colorectal cancer, head and neck squamous Among patients with cancer, kidney cancer, liver cancer, prostate cancer, and melanoma, although the prognosis of patients in the Low Index group is poor, there are more mutation loads and / or tumor neoantigens, suggesting that patients in this group are more likely to benefit from immunotherapy. benefit.

Cellular and genetic signatures and methods of using same for subcategorizing stage III melanoma tumors are described herein. The signatures and methods are particularly useful with regard to establishing more distinct criteria on which basis to differentiate stage IIIB and IIIC melanoma patients. Assessment of the cellular and genetic signatures of a melanoma sample using methods described herein yields information on which basis differential survival duration and sensitivity to various cancer therapies can be predicted for a Stage IIIB or Stage IIIC melanoma patients. As described herein, gene expression profiling, determination of mitotic index (MI), and quantification of tumor infiltrating leukocytes (TILs) and CD3+ cells in metastatic lesions may be utilized to predict or assess drug response, drug sensitivity, and clinical outcome in metastatic melanoma patients.

Methods and materials for inducing anti-tumor responses in melanoma patients are disclosed. These methods and materials involve gp100-derived polypeptides that contain both a helper T-cell epitope and a cytotoxic T-cell epitope.

The invention discloses an application of SLC12A3 and / or SLC12A9 as an index for treatment and prognosis detection of uveal melanoma. The invention further discloses a calculation model for predicting uveal melanoma prognosis and a medicine for preventing or treating uveal melanoma. The invention provides a new method for prognosis monitoring and treatment of uveal melanoma patients.